Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atabecestat in Asymptomatic Individuals at Risk for Alzheimer's Dementia
jRCT2080223162Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of atabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Started Apr 2016; status: terminated.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223162.